Two Alabama Medical Cannabis Dispensaries Set to Open Next Week

Two dispensaries expected to open, according to the Alabama Reflector

The Alabama Reflector reported on Oct. 29, 2026, that two medical cannabis dispensaries in Alabama are expected to open next week.

That's all the published signal establishes. The Reflector's headline gives the number of dispensaries and the timing. In the material CannIntel reviewed, it doesn't identify the operators, the addresses or the exact opening dates.

CannIntel hasn't independently confirmed those details, and we aren't filling the gaps with assumptions. Readers should treat "next week" as the Reflector's reporting. Not as a regulatory commitment. Openings in new medical markets often shift by days when inspections, inventory transfers or local approvals run long.

Still, the direction is clear. Alabama has spent more than five years between authorizing a medical cannabis program and watching a patient walk into a licensed storefront. Two open doors would be the first visible proof the program can function.

How the 2021 law set the stage

Alabama authorized medical cannabis through Act 2021-450, signed by Gov. Kay Ivey in May 2021 after Sen. Tim Melson, R-Florence, carried the bill.

The law created the Alabama Medical Cannabis Commission, known as the AMCC, and gave it authority to license cultivators, processors, dispensaries, transporters and a state testing laboratory. It also assigned the commission responsibility for registering physicians and issuing patient cards.

What can be sold is limited by the statute. Smoking and vaping of raw plant material aren't permitted under the program, so dispensaries are built around forms such as tablets, capsules, oils, topicals and similar products. Patients must hold a physician's certification for a qualifying condition, and the commission administers the registry.

Those guardrails matter for anyone trying to size the Alabama market. A medical-only program with a restricted product list and a physician gate behaves differently from the adult-use markets in states like Illinois or Colorado. Demand will build through the clinic, not the storefront.

Why it took so long

Licensing litigation, not the statute itself, is the main reason Alabama's program took years to approach retail sales.

After the AMCC began awarding business licenses, competing applicants challenged the process in court, the commission's awards were repeatedly put on hold, and open-meetings and scoring disputes became the central fights. Applicants who lost out argued the process was flawed, and the commission had to revisit its work more than once.

That sequence is a familiar one in limited-license states. When a market is capped, every denied applicant has a financial reason to sue. Alabama's cap made the legal exposure larger than the statute's drafters may have intended.

The result: a program that existed on paper. Patients had no lawful place to buy product. Some residents with qualifying conditions kept traveling or relying on the illicit market. That's the gap these two dispensaries are meant to start closing.

What operators, patients and investors should watch

Two dispensaries won't make a functioning market, so the early signals will be supply, pricing and patient registration numbers.

Operators will first ask whether licensed cultivators and processors can deliver tested, compliant product in volume. A dispensary with thin shelves can't build a patient base. Simple as that. Supply chain readiness, including state-required lab testing, will determine whether the first stores stay stocked.

For patients, the questions are practical. How many registered physicians are available, how quickly can a certification be obtained, and how far must a patient travel to reach one of two stores? Alabama is a large state with a dispersed population. Two locations can't serve everyone.

Investors, meanwhile, should read this cautiously. Early medical markets tend to start slowly, and pricing in a restricted-product program rarely looks like pricing elsewhere. We won't speculate on revenue because the signal supplies no sales data. That absence is itself informative: no one outside the commission and the operators can yet say what demand looks like.

Not yet. That's the honest answer on market size.

For full background on this story, see the CannIntel topic hub on the Alabama Medical Cannabis Program, where we track licensing actions, court rulings and commission votes as they occur.

The next signals: official confirmation from the AMCC of the operators and opening dates, and the first public count of registered patients and certifying physicians. If either lags the Reflector's timeline, the "next week" label will matter less than the paperwork behind it.